How did GMED's revenue and expenses shift in Q4 2024?

**Globus Medical (GMED) experienced a significant increase in revenue during Q4 2024, but faced challenges in managing expenses.** Here's a detailed analysis: 1. **Revenue Shift**: - GMED's total revenue for Q4 2024 was $657.29 million. - This represents a substantial surge compared to the previous quarter, primarily driven by the inclusion of NuVasive in their merger and an overall increase in volume of spine product sales and enabling technology products and services. 2. **Expense Shift**: - Unfortunately, the data for GMED's expenses in Q4 2024 is not available. - However, from Q3 2024, we know that SG&A expenses increased by 54.1% to $240.7 million, and research and development expenses rose by 20.6% to $35.4 million. - The cost of sales saw a significant surge, leading to a contraction in gross margin by 794 basis points to 56.8%. 3. **Insights into Financial Health**: - Despite the increase in expenses, GMED's strong revenue growth and ability to exceed market expectations in sales and earnings suggest resilience in their financial performance. - The company's focus on innovation and product launches, as well as strategic market expansions, particularly in the United States, has been pivotal to its revenue growth. 4. **Market Position and Future Outlook**: - GMED's institutional ownership stands at 95.16%, indicating strong confidence from long-term investors. - The company's market cap is substantial at $11.14 billion, with a P/E ratio of 122.06, suggesting high investor confidence in future earnings potential. In conclusion, GMED's Q4 2024 financials reflect a company that continues to leverage strategic acquisitions and market expansions to drive revenue growth, despite facing challenges in managing costs and maintaining gross margins.